Physician profile
Eric William Johnston
NPI 1114916053
$9,309.77
in general payments reported to CMS, 2019-2025
25 companies · $1,741 in 2025
The $1,741 reported for 2025 was more than what 87% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $591 · 2021: $1,812 · 2022: $1,744 · 2023: $1,580 · 2024: $1,842 · 2025: $1,741.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,163.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,162.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $3,302.16 | 2019-2025 | Clareon, Centurion, Clareon Panoptix Pro |
| Bausch & Lomb Americas INC. | $1,376.60 | 2022-2025 | Xiidra, Miebo, Envista Mx60 Iol |
| Glaukos Corporation | $1,016.59 | 2021-2024 | Istent Trabecular Micro-Bypass System Model Is3, Photrexa Cross-Linking Kit, Photrexa Viscous and Photrexa |
| Tarsus Pharmaceuticals, INC. | $656.45 | 2024-2025 | Xdemvy |
| Kala Pharmaceuticals, INC. | $367.22 | 2021-2022 | |
| Oyster Point Pharma, INC. | $343.13 | 2022-2025 | Tyrvaya |
| Johnson & Johnson Surgical Vision, INC. | $331.07 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $262.63 | 2021-2023 | |
| Harrow Eye, LLC | $252.30 | 2024-2025 | Vevye |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $198.33 | 2021 | |
| Ivantis, INC | $179.79 | 2021 | |
| Sight Sciences, INC. | $160.85 | 2024 | Omni Surgical System |
| Sun Pharmaceutical Industries INC. | $154.25 | 2019-2025 | |
| Abbvie INC. | $131.62 | 2022-2024 | |
| Dompe US, INC. | $119.90 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $115.13 | 2025 | Light Adjustable Lens (Lal), Rxsight Contact Lens, Rxsight Injector Handpiece |
| Amgen INC. | $96.75 | 2024-2025 | Tepezza |
| Allergan, INC. | $54.36 | 2021 | |
| Johnson & Johnson Vision Care, INC. | $39.98 | 2023 | Acuvue |
| Biotissue Holdings INC. | $39.00 | 2024 | |
| Vantage Technology LLC | $29.57 | 2019 | |
| Beaver-Visitec International, INC. | $24.35 | 2021 | |
| Aerie Pharmaceuticals, INC. | $23.77 | 2021 | |
| Thea Pharma INC. | $18.82 | 2023 | Iyuzeh |
| Ocular Therapeutix, INC. | $15.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Johnston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.